{
  "docId": "019dd923-622c-750b-8b99-bca3fd68622d",
  "docSlug": "4c8fe6013c68",
  "documentTitle": "iRhythm Technologies, Inc. (IRTC)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 100,
  "pageCount": 101,
  "prevPage": 99,
  "nextPage": 101,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 112,
  "notes": "The slide argues that iRhythm's technology is commoditized and less rigorous than peers, justifying a lower valuation multiple.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "comparison_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-bca3fd68622d/100",
  "deckHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d#slide-100",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Based on business similarities, we believe there is a strong case that iRhythm should be valued in-line with other outpatient testing and services companies, which trade at materially lower multiples.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0396-73da-b8fa-49b77c981937",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "EV/Rev: 6.7x",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-0396-73da-b8fa-4dfd59dd411c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.96,
        "x": 0.02,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "Wall Street analysts often compare iRhythm to leading medical device companies. By contrast, we believe iRhythm's products (1) employ highly commoditized technology (electrical sensors), (2) are not R&D intensive, as they have targeted a single product for a single indication the entire life of the Company, (3) are only attached by adhesive on the surface of the patient's skin, which represents a lower threshold for safety compared to a device being inserted into the body, and (4) are very low-priced wearables as opposed to products consisting of, or accompanied by, a high-priced piece of capital equipment. In addition, the Company's tests are simply not as scientifically rigorous as services such as genetic testing. Based on business similarities, we believe there is a strong case that iRhythm should be valued in-line with other outpatient testing and services companies, which trade at materially lower multiples. While investors may protest that iRhythm's high multiple is justified by its anticipated revenue growth, we note that iRhythm is experiencing declining revenue growth, which is often associated with multiple contraction.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8460afaf-4276-4777-b254-665c07edce5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.02,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: S&P Capital IQ",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce9e8bed-26a5-44d2-ac4f-6616430f5796",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.82,
        "x": 0.14,
        "y": 0.44
      },
      "kind": "table",
      "text": "iRhythm Comparable Company Analysis table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e251e1d3-4abd-4356-a85b-f97dbfb42859",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.31,
        "y": 0.03
      },
      "kind": "title",
      "text": "Our Comparable Company Analysis Suggests iRhythm Is Trading At Least At A 100% Premium",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b8be172-37f6-4c9f-ac13-001a664d526e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "f6dcbeae-7334-40de-a504-54ba489b6ada",
      "evidence": "Comparison of iRhythm against medical device and testing services peers to justify valuation premium.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}